Evidence map›Paper›PMID 31947545›Full record

ArticleMetabolites2020

Comprehensive Circulatory Metabolomics in ME/CFS Reveals Disrupted Metabolism of Acyl Lipids and Steroids.

Arnaud Germain, Dinesh K Barupal, Susan M Levine, Maureen R Hanson

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Metabolites, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05273372 (A Randomized Double Blind Placebo Controlled Trial to Determine the Effects of Oxaloacetate on Improving Fatigue in ME/CFS), which is not on this map. Cited by 67 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 2 pooled it
8.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05273372 nacompletednot on this mapstarted 2022, after this paper: background citation

A Randomized Double Blind Placebo Controlled Trial to Determine the Effects of Oxaloacetate on Improving Fatigue in ME/CFS

TypeinterventionalSponsorTerra Biological LLCRan2022 to 2024Enrolled82ConditionsMyalgic Encephalomyelitis, Chronic Fatigue Syndrome, FatigueArmsPlacebo, Medical Food - Anhydrous Enol-Oxaloacetate
3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 2 syntheses or guidelines pooled it, 89 citations in OpenAlex.

  1. Recent research in myalgic encephalomyelitis/chronic fatigue syndrome: an evidence map.Health technology assessment (Winchester, England) · 2025
    Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Anti-fatigue mechanism ofFrontiers in cell and developmental biology · 2026
    Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Observational
  17. Article
  18. Article
  19. Article
  20. Article

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Arnaud GermainDepartment of Molecular Biology and Genetics, Cornell University, Ithaca, NY 14853, USA.
Dinesh K BarupalUC Davis Genome Center-Metabolomics, University of California, Davis, CA 95616, USA.
Susan M LevineUC Davis Genome Center-Metabolomics, University of California, Davis, CA 95616, USA.
Maureen R HansonUC Davis Genome Center-Metabolomics, University of California, Davis, CA 95616, USA.
Cornell University · USUniversity of California, Davis · US

Funding

Probing the Pathophysiology of ME/CFS through Proteomics and MetabolomicsU54NS105541 · NINDS · CORNELL UNIVERSITY · PI KELLER, BETSY A · 2017 to 2021
$9.4M
Immune cell gene expression and predictive models in CFSR01AI107762 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI ELEMENTO, OLIVIER, HANSON, MAUREEN REBECCA · 2013 to 2017
$3.0M
Division of Intramural Research, National Institute of Allergy and Infectious Diseases 1 R01 AI107762NIAID NIH HHS R01 AI107762NINDS NIH HHS U54 NS105541NINDS NIH HHS U54NS105541
6 · The paper itself

Abstract

The latest worldwide prevalence rate projects that over 65 million patients suffer from myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), an illness with known effects on the functioning of the immune and nervous systems. We performed an extensive metabolomics analysis on the plasma of 52 female subjects, equally sampled between controls and ME/CFS patients, which delivered data for about 1750 blood compounds spanning 20 super-pathways, subdivided into 113 sub-pathways. Statistical analysis combined with pathway enrichment analysis points to a few disrupted metabolic pathways containing many unexplored compounds. The most intriguing finding concerns acyl cholines, belonging to the fatty acid metabolism sub-pathway of lipids, for which all compounds are consistently reduced in two distinct ME/CFS patient cohorts. We compiled the extremely limited knowledge about these compounds and regard them as promising in the quest to explain many of the ME/CFS symptoms. Another class of lipids with far-reaching activity on virtually all organ systems are steroids; androgenic, progestin, and corticosteroids are broadly reduced in our patient cohort. We also report on lower dipeptides and elevated sphingolipids abundance in patients compared to controls. Disturbances in the metabolism of many of these molecules can be linked to the profound organ system symptoms endured by ME/CFS patients.

Indexed as

acyl cholinesdipeptideslipidsME/CFSmetabolomicssteroids

Identifiers

PMID31947545
PMCPMC7023305
OpenAlexW3000367911

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.